Targeting specific proteins to treat chronic lymphocytic leukemia.
XBP1 Inhibition and STING activation for the treatment of cancer
This study is looking at a new way to treat chronic lymphocytic leukemia (CLL) by using a combination of a drug that targets a protein helping cancer cells grow and another that boosts the immune system to fight the cancer better, especially for patients who haven't had success with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11055977 on NIH RePORTER |
What this research studies
This research investigates new treatment options for chronic lymphocytic leukemia (CLL), a common blood cancer in adults. It focuses on inhibiting a protein called XBP-1, which is crucial for the growth and survival of CLL cells, and activating another protein called STING to enhance the immune response against these cancer cells. The study aims to combine a drug that suppresses XBP-1 with a STING activator to improve treatment outcomes for patients who have not responded well to existing therapies. By exploring this combination, the research seeks to provide a more effective approach to managing CLL.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with chronic lymphocytic leukemia who have not responded well to standard treatments.
Not a fit: Patients with other types of cancer or those who do not have chronic lymphocytic leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with chronic lymphocytic leukemia, particularly those who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Hu, Chih-Chi Andrew — Methodist Hospital Research Institute
- Study coordinator: Hu, Chih-Chi Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.